Free Republic

Scientists have identified an off-patent drug that can be repurposed to prevent COVID-19—and may be capable of protecting against future variants of the virus—in research involving a unique mix of "mini-organs," donor organs, animal studies and patients. The research showed that an existing drug used to treat a type of liver disease is able to "lock" the doorway by which SARS-CoV-2 enters our cells, a receptor on the cell surface known as ACE2. Because this drug targets the host cells and not the virus, it should protect against future new variants of the virus as well as other coronaviruses that...

Dr. Peter McCullough is an internist, cardiologist, epidemiologist, a full professor of medicine at Texas A&M College of Medicine in Dallas, USA. He also has a master's degree in public health and is known for being one of the top five most-published medical researchers in the United States and is the editor of two medical journals.McCullough et al. Reviews in Cardiovascular Medicine, 2020McCullough et al. 2020In this Sept 14, 2021 interview with Peter Breggin MD, author of Talking Back to Prozac, Dr. Peter McCullough discusses the routine use of diluted (1%) Povidone Iodine mouth wash in the dental office as...

Abstract COVID 19 is known to cause immune dysregulation and vitamin D is a known immunomodulator. This study aims to objectively investigate the impact of Pulse D therapy in reducing the inflammatory markers of COVID-19. Consented COVID-19 patients with hypovitaminosis D were evaluated for inflammatory markers (N/L ratio, CRP, LDH, IL6, Ferritin) along with vitamin D on 0th day and 9th/11th day as per their respective BMI category. Subjects were randomised into VD and NVD groups. VD group received Pulse D therapy (targeted daily supplementation of 60,000 IUs of vitamin D for 8 or 10 days depending upon their BMI)...